Scarica l'app Stockscreener
0.4953
0.04%
-0.0002
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Nextcure Inc Borsa (NXTC) Ultime notizie
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times
NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq
First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks
NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus
NextCure, Inc. SEC 10-Q Report - TradingView
NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan
NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
It’s Worth A Gamble To Have A Position In Applied Therapeutics Inc (NASDAQ: APLT) At $0.32. - Marketing Sentinel
NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks
NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia
NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India
NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia
NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa
NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
2 Net Current Asset Value Stocks to Consider - GuruFocus.com
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN
NextCure Reports 2024 Financials and Strategic Progress - TipRanks
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times
NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq
Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan
NextCure Inc. (NXTC) reports earnings - qz.com
Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com
NextCure stock plunges to 52-week low, hits $0.69 - MSN
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):